TO THE EDITOR
We read with interest the report entitled 'Induction of apoptosis by 2-chlorodeoxyadenosine in B cell chronic lymphocytic leukemia' by Castejon et al. 1 The authors demonstrated that spontaneous apoptosis occurred in B cell chronic lymphocytic leukemia (CLL) cells incubated in the absence of the drug, but the level of apoptosis induced by 2-chlorodeoxyadenosine (2-CDA) was significantly higher after 2 days of culture. Also, the authors emphasized that the occurrence of this phenomenon was associated with an in vitro 2-CDA-concentration equivalent to that therapeutically achieved after in vivo treatment. We would like to report our experience on 2-CDAinduced apoptosis extending the information on fludarabine (FAMP)-and chlorambucil (CLB)-induced apoptosis in CLL.
Freshly isolated cells from 19 previously untreated CLL patients were incubated for 4 days with either no drug or CLB (Sigma, St Louis, MO, USA) 1 g/ml or FAMP (Fludara; Schering, Germany) 1 g/ml or 2-CDA (Leustatin, Ortho Biotech, Raritan, NJ, USA) 1.125 g/ml. These drug concentrations were comparable to those obtained in vivo after standard-dose treatment. The cell distribution of DNA content was investigated by flow cytometry as previously described by Nicoletti et al. 2 The propidium iodide-fluorescence of the nuclei was measured by an EPICS profile II flow cytometer (Coulter Electronics, Hialeah, FL, USA). The flow cytometer was aligned using the highest quality 10 m fluorospheres (Coulter EPICS, DNA-check beads) having a population % HPCV of less than 2% for FL2 and FS. The nuclei traversed the light beam at 488 nm laser. A 600 nm dichroic mirror and a 635 band pass filter (bandwidth 20 nm) were used for collecting the PI red fluorescence, and data of the hypodiploid DNA peak were acquired in logarithmic scale. Table 1 shows the results of our study. After 4-day culture, 22.3% of CLL cells showed evidence of spontaneous Table 1 Percentage of apoptotic nuclei after 4 days of incubation in the absence of any drug (spontaneous apoptosis) and in the presence of 2-CDA 1.25 g/ml, FAMP apoptosis. The percentage of apoptotic nuclei significantly enhanced up to 40.9% and 39.4%, respectively, in the presence of 2-CDA and FAMP, while no change was observed in the presence of CLB. Our data are in line with the results of Castejon with regard to the effect of 2-CDA in inducing apoptosis on CLL cells, using therapeutically achievable drug concentrations. Moreover, we ascertained that FAMP was also able to induce apoptosis to the same extent as 2-CDA. The apparent no-effect of CLB on apoptosis could be due to the time where the phenomenon was assessed and to the drug concentration employed. The Castejon study 1 showed that degree of apoptosis induced by 2-CDA was dose-dependent and the comparison with the spontaneous apoptosis became statistically significant after 48 h of culture. Similarly, the CLB concentration we used in vitro could be insufficient to overcome spontaneous apoptosis; however, different to 2-CDA, high-dose CLB may be clinically employed in CLL with a higher response rate than standard-dose CLB 3 and CHOP, 4 and similar results when compared to FAMP. 5 In conclusion, our results coupled with those of Castejon et al 1 support the notion that both 2-CDA and FAMP activate a program of cell death by a drug concentration equivalent to that therapeutically achieved in vivo, after standard-dose schedules. In vitro apoptosis induction by high-dose CLB should be investigated, as in the clinical setting high-dose CLB improves the number of clinical responses. 
